Dr. Greg Beatty is an associate professor of medicine at the Perelman School of Medicine and in the Division of Hematology/Oncology within the Abramson Cancer Center at the University of Pennsylvania. Dr. Beatty is Director of Clinical and Translational Research for the Pancreatic Cancer Research Center at the University of Pennsylvania. He graduated from Bucknell University (Chemical Engineering) and obtained his PhD (Immunology) from the University of Pennsylvania. He then earned his MD from the Perelman School of Medicine at the University of Pennsylvania and completed a residency in Internal Medicine and fellowship in medical oncology at the University of Pennsylvania. As an NIH-funded investigator at Penn Medicine, Dr. Beatty directs a discovery laboratory that incorporates both basic science research and clinical investigation to inform the development of novel immunotherapies. Dr. Beatty has led pivotal first-in-human clinical trials investigating CAR T cells for the treatment of pancreatic cancer. He has also led studies investigating strategies to target cancer inflammation, including CD40 agonists and inhibitors of IDO and JAK. He has published more than 70 peer-reviewed manuscripts with senior- or first-author papers in high-impact journals such as Science, Nature, Nature Immunology, and Cancer Discovery. He is internationally recognized for his expertise in pancreas cancer and cancer immunotherapy.
Nationally, Dr. Beatty is a member of Pancreatic Cancer Action Network Board of Scientific Advisors. He is an elected member of the American Society of Clinical Investigation and recipient of several awards from the Doris Duke Charitable Foundation, Stand Up To Cancer, Damon Runyon Cancer Research Foundation, Lustgarten Foundation, and Mark Foundation for Cancer Research.